Over the past few years, real-world evidence (RWE) and health economics and outcomes research (HEOR) have shifted from supporting roles to central levers in how pharma designs trials, secures access, and manages the lifecycle of medicines. Regulators are…
APICES CRO is pleased to announce its contribution to the GEOCP-SEOR study. This is a RWE Study in Non Small Cell Lung Cancer (NSCLC), recently featured in the Cancers Journal. The study evaluates and provide real-world insights into the…
Insights from Óscar Salamanca, CEO of APICES, President of the Spanish Association of Clinical Research Companies (AECIC) Artificial intelligence (AI) is transforming the landscape of clinical research and drug development. From predictive analytics and trial optimization to patient…
Key take-aways from the ESMO – European Society for Medical Oncology Congress in Berlin, 17-21 October, 2025 The 2025 edition of the European Society for Medical Oncology (ESMO) Congress, held in Berlin from October 17-21, offered a wealth…
APICES CRO is pleased to announce its contribution to the CANTABRICO study. This is a Phase IIIb clinical trial in Small Cell Lung Cancer (SCLC), recently featured in the Elsevier Lung Cancer Journal. The study evaluates first-line treatment in…
If you’re a biotech CEO weighing where and with whom to run oncology clinical trials in Europe, the margin for error is thin. Even though the EU’s Clinical Trials Regulation (CTR 536/2014) has standardized many processes via CTIS,…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in PALBOBIN Trial, a Phase IB clinical trial in Breast Cancer (TNBC). This acknowledgement was highlighted in the Journal of Cancer Research Communications. APICES…
We are thrilled to announce that Egle Pavyde has joined APICES CRO as Vice President of Business Development. With over 10 years of experience in the clinical trials field, she brings the expertise needed to help APICES’ clients…
Biotechs operate under enormous pressure: they need to deliver solid scientific results, meet tight deadlines, manage limited resources, and navigate an increasingly demanding regulatory environment in our clinical research. With no room for error, success depends on finding…
We are proud to announce that APICES has been acknowledged for its ongoing collaboration in the CABOMAYOR Trial, a Phase II clinical trial in metastatic renal cell carcinoma (mRCC). This acknowledgement was highlighted in the Journal of Geriatric…
